Journal of Clinical Oncology
Articles in this Issue
First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.
6508 Background: Patients with relapsed or refractory T-lymphoblastic leukemia/Peripheral T-Cell Lymphoma (R/R T-ALL/PTCL)...
Assessing barriers to cancer clinical trial participation at an urban inner-city safety net hospital.
e17152 Background: In 2025, the FDA approved 14 therapies across multiple malignancies, reflecting advances in tumor genom...
Structured interventional strategies to prevent and reduce burnout in medical oncologists: The Resilience–Spanish Society of Medical Oncology (SEOM) multicenter project.
TPS12165 Background: Burnout is highly prevalent among young medical oncologists, with an estimated incidence exceeding 70...
Early ctDNA dynamics assessed by a personalized whole-genome sequencing-based assay as a predictor of outcomes with immune checkpoint blockade in advanced melanoma.
3053 Background: Circulating tumor DNA (ctDNA) is an emerging biomarker for assessing treatment outcomes and monitoring di...
An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.
2509 Background: Pancreatic cancer has a high postoperative recurrence rate. Although adjuvant chemotherapy is standard of...
Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC): Primary analysis of SAKK 06/19.
4503 Background: Perioperative chemo-IO is a new standard for MIBC but pathological complete remission (pCR) rates remain...
Prognostic performance of a multimodal artificial intelligence histopathology-based tool versus the 21-gene recurrence score in early-stage breast cancer.
559 Background: Genomic classifiers are widely used to assess risk of distant metastasis (DM) and inform chemotherapy (CT)...
Longitudinal cytokine and transcriptomic profiling of immune-related adverse events in early-stage TNBC treated with pembrolizumab.
e12640 Background: Pembrolizumab-based chemo-immunotherapy improves outcomes in early-stage triple-negative breast cancer...
Epidemiological trends and burden of multiple myeloma mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e19548 Background: Multiple myeloma (MM) is an increasingly important contributor to cancer-related mortality worldwide, y...
Diagnostic efficiency in precision oncology: Quantifying time to treatment initiation for biomarker-positive vs biomarker-negative metastatic NSCLC.
e20760 Background: A primary concern in the integration of Next-Generation Sequencing (NGS) into first-line (1L) metastati...
Clinicopathological predictors of survival and disease progression in melanoma: A real-world cohort from the MENA region.
e21601 Background: Melanoma exhibits marked heterogeneity in clinical behavior, with survival outcomes strongly influenced...
Perception and awareness of cancer immunotherapy among healthcare professionals and students at a tertiary referral center in the MENA region.
e23222 Background: Cancer immunotherapy has shaped the management of several malignancies; however, its safe and effective...
Genomic determinants of radiation necrosis in diffuse glioma patients.
2053 Background: Diffuse gliomas are the most common primary brain tumors, requiring multimodal therapy. Radiotherapy (RT)...
Screening for intrinsic and acquired resistance mutations to anti-EGFR in real-world MSS colorectal cancer data.
3557 Background: Anti-EGFR (cetuximab, panitumumab) plus doublet chemotherapy is the first line standard of care for metas...
PEMBROCABOSARC: A phase II trial combining pembrolizumab and cabozantinib in patients with advanced undifferentiated pleomorphic sarcoma.
11514 Background: There is a growing rationale for combining immunotherapy and VEGF inhibitors in sarcoma. We report resul...
Comparative efficacy and safety of systemic therapies in high-risk hormone-sensitive prostate cancer: A network meta-analysis of 13 phase III randomized trials.
5081 Background: Treatment intensification improves survival in hormone-sensitive prostate cancer (HSPC). However, direct...
Necitumumab plus pembrolizumab and chemotherapy for untreated advanced squamous NSCLC: Phase I/II NEJ048A/NEXUS.
8528 Background: EGFR blockade enhances tumor antigen presentation and may potentiate PD-1 inhibition. This phase I/II stu...
Chemotherapy-free neoadjuvant strategy in HR+/HER2− early breast cancer: Efficacy of CDK4/6 inhibitors plus endocrine therapy compared to chemotherapy-sequenced approach.
e12671 Background: In HR+/HER2- breast cancer (BC), neoadjuvant chemotherapy (NACT) remains a standard in many regions des...
20-year trends in socioeconomic disparities in breast cancer care for patients aged < 65 years old.
1559 Background: Socioeconomic disparities (SES) in cancer care have been well described, especially for younger patients...
De-escalation of axillary surgery in clinically node-negative early-stage HR-positive, HER2-negative breast cancer.
e12624 Background: The role of axillary surgery in early-stage breast cancer continues to evolve. While sentinel lymph nod...
Phase II study of mirogabalin for oxaliplatin-associated chemotherapy-induced peripheral neuropathy in gastrointestinal cancer: The SmiliNg trial.
12057 Background: Oxaliplatin is a key drug in the treatment of unresectable advanced or recurrent gastrointestinal (GI) c...
Cancer during pregnancy and child health perspectives: Evidence from real-world data.
11013 Background: Pregnancy-associated cancer (PAC), is rare but increasingly encountered, likely reflecting delayed child...
Tumor histone H3 lysine 18 lactylation for the prediction of immunotherapy efficacy in patients with advanced non–small cell lung cancer.
e20676 Background: Clinical benefit from immune checkpoint inhibitors (ICIs) in advanced non–small cell lung cancer (NSCLC...
Timing of irAE and survival in NSCLC.
e20659 Background: Immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI) therapy are associated w...
Impact of poor performance status on outcomes with immune checkpoint inhibitors in advanced non–small cell lung cancer: A systematic review and meta-analysis.
e20617 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non–small cell lung cancer (NSCL...